Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
JMJD1A CRISPR/Cas9 KO Plasmid (h): sc-403423
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- JMJD1A CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the JMJD1A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: JMJD1A Antibody (H-1): sc-398946
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JMJD1A CRISPR/Cas9 KO Plasmid (h) | sc-403423 | 20 µg | $397.00 |
Overview
KDM3A encodes JMJD1A, a Jumonji C (JmjC) domain–containing histone demethylase that primarily removes repressive H3K9me1/2 marks to promote transcriptional activation. By reshaping chromatin accessibility, JMJD1A modulates programs linked to hormone receptor signaling, hypoxia responses, metabolic gene expression, and cell fate decisions. Its activity intersects with epigenetic regulation of enhancer and promoter states, influencing pathways governing proliferation, differentiation, and stress adaptation. Dysregulated KDM3A/JMJD1A expression or function has been associated with altered transcriptional networks observed across multiple cancer contexts and metabolic phenotypes, supporting investigation into epigenetic vulnerabilities.
JMJD1A CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KDM3A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KDM3A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KDM3A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish JMJD1A protein expression.
This CRISPR knockout system enables efficient generation of KDM3A-deficient cell models for investigation of JMJD1A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting KDM3A exon(s) critical for JMJD1A function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple KDM3A genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by JMJD1A CRISPR/Cas9 KO Plasmid (h) and JMJD1A CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KDM3A locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by JMJD1A HDR Plasmid (h) and JMJD1A HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KDM3A homology arms to support homology-directed repair at defined KDM3A target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.